Compare CTBI & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CTBI | COLL |
|---|---|---|
| Founded | 1903 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 1.2B |
| IPO Year | 1995 | 2015 |
| Metric | CTBI | COLL |
|---|---|---|
| Price | $61.90 | $32.48 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $59.50 | $51.17 |
| AVG Volume (30 Days) | 77.6K | ★ 520.9K |
| Earning Date | 04-17-2026 | 05-07-2026 |
| Dividend Yield | ★ 3.44% | N/A |
| EPS Growth | ★ 17.79 | N/A |
| EPS | ★ 5.43 | 1.73 |
| Revenue | N/A | ★ $780,567,000.00 |
| Revenue This Year | $14.02 | $5.93 |
| Revenue Next Year | $4.30 | N/A |
| P/E Ratio | ★ $11.35 | $19.22 |
| Revenue Growth | N/A | ★ 23.62 |
| 52 Week Low | $44.60 | $23.23 |
| 52 Week High | $65.79 | $50.79 |
| Indicator | CTBI | COLL |
|---|---|---|
| Relative Strength Index (RSI) | 58.79 | 29.65 |
| Support Level | $56.42 | $31.01 |
| Resistance Level | $65.64 | $32.92 |
| Average True Range (ATR) | 1.77 | 1.27 |
| MACD | 0.36 | 0.14 |
| Stochastic Oscillator | 94.12 | 11.10 |
Community Trust Bancorp Inc is a bank holding company. The Bank owns all the capital stock of one commercial bank and one trust company, serving small and mid-sized communities in eastern, north-eastern, central, and south-central Kentucky, southern West Virginia, and north-eastern Tennessee. Through its subsidiaries, the Bank is engaged in commercial and personal banking and trust and wealth management activities, which include accepting time and demand deposits; making secured and unsecured loans to corporations, individuals, and others; providing cash management services to corporate and individual customers; issuing letters of credit; renting safe deposit boxes; and providing funds transfer services. The company operates in one reportable segment: community banking services.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.